Catamaran Bio has weighed anchor with a $42 million first-round financing that will be used to pull its off-the-shelf natural killer (NK) cell therapies for cancer through early-stage development ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

NK (natural killer) cells are a population of lymphocytes with both innate and adaptive immune features. They produce cytotoxic molecules and can eliminate infected cells or cancer cells. Lactate ...